FGFR1 has recently emerged as a promising target in NSCLC after the gene was reported as amplified in about 20% of lung SCC [13]–[14], [25], leading to early phase clinical trials of anti-FGFR1 agents in FGFR1-amplified NSCLC. This evidence concerns the gene FGFR1 and non-small cell lung carcinoma.